AUROPHARMA1,666.00

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹96,761 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+6.1+7.7
EBITDA+4.0+8.2
Net Income+0.6+5.1
EPS (adj.)+0.5+5.1
Total Assets+17.5+13.9
Total Equity+16.0+12.7
Free Cash Flow+72.4
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.